5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)

Journal article

Peer reviewed

I. E. Ahn, D. M. Brander, Y. Ren, Y. Zhou, S. Tyekucheva, H. A. Walker, R. Black, J. Montegaard, A. Alencar, L. Shune, …

Hematological oncology, Vol.41(S2), pp.231-233

2023-06

Metrics

1 Record Views

Title: 5‐YEAR (Y) FOLLOW‐UP OF A PHASE 2 STUDY OF IBRUTINIB PLUS FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (IFCR) AS INITIAL THERAPY FOR YOUNGER CLL PATIENTS (PTS)
Creators: I. E. Ahn - Dana–Farber Cancer Institute
D. M. Brander - Duke University
Y. Ren - Dana-Farber Cancer Institute
Y. Zhou - Dana-Farber Cancer Institute
S. Tyekucheva - Dana-Farber Cancer Institute
H. A. Walker - Dana-Farber Cancer Institute
R. Black - Dana-Farber Cancer Institute
J. Montegaard - Dana-Farber Cancer Institute
A. Alencar - Sylvester Comprehensive Cancer Center
L. Shune - The University of Kansas Cancer Center
M. Omaira - West Michigan Cancer Center
C. A. Jacobson - Dana–Farber Cancer Institute
P. Armand - Dana-Farber Cancer Institute
S. Ng - Dana-Farber Cancer Institute
J. Crombie - Dana-Farber Cancer Institute
D. C. Fisher - Dana-Farber Cancer Institute
A. S. LaCasce - Dana-Farber Cancer Institute
J. Arnason - Beth Israel Deaconess Medical Center
E. P. Hochberg - Beth Israel Deaconess Medical Center
R. W. Takvorian - Beth Israel Deaconess Medical Center
J. S. Abramson - Massachusetts General Hospital
J. R. Brown - Dana–Farber Cancer Institute
M. S. Davids - Dana–Farber Cancer Institute
Publication Details: Hematological oncology, Vol.41(S2), pp.231-233
Academic Unit: Miller School of Medicine; UMMG Dept of Medicine - Hematology/Oncology
Language: English
Resource Type: Journal article
Record Identifier: 991031821237302976